Advertisement
BWAY vs DXR
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BWAY is a StrongBuy and DXR is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BWAY’s FA Score shows that 0 FA rating(s) are green whileDXR’s FA Score has 1 green FA rating(s).
- BWAY’s FA Score: 0 green, 5 red.
- DXR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BWAY’s TA Score shows that 3 TA indicator(s) are bullish while DXR’s TA Score has 3 bullish TA indicator(s).
- BWAY’s TA Score: 3 bullish, 5 bearish.
- DXR’s TA Score: 3 bullish, 7 bearish.
Price Growth
BWAY (@Medical/Nursing Services) experienced а -10.46% price change this week, while DXR (@Pharmaceuticals: Other) price change was -1.45% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -3.35%. For the same industry, the average monthly price growth was -0.90%, and the average quarterly price growth was +13.54%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.34%. For the same industry, the average monthly price growth was -0.30%, and the average quarterly price growth was +23.34%.
Reported Earning Dates
BWAY is expected to report earnings on Mar 11, 2026.
Industries' Descriptions
@Medical/Nursing Services (-3.35% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (-1.34% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| BWAY | DXR | BWAY / DXR | |
| Capitalization | 454M | 73M | 622% |
| EBITDA | 9.52M | N/A | - |
| Gain YTD | 20.557 | -15.017 | -137% |
| P/E Ratio | 71.45 | 78.34 | 91% |
| Revenue | 49.1M | 3.31M | 1,483% |
| Total Cash | 71.5M | N/A | - |
| Total Debt | 6.75M | 263K | 2,567% |
BWAY | DXR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 85 | 58 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 79 Overvalued | 90 Overvalued | |
PROFIT vs RISK RATING 1..100 | 35 | 94 | |
SMR RATING 1..100 | 67 | 84 | |
PRICE GROWTH RATING 1..100 | 37 | 55 | |
P/E GROWTH RATING 1..100 | 91 | 2 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BWAY's Valuation (79) in the Medical Specialties industry is in the same range as DXR (90). This means that BWAY’s stock grew similarly to DXR’s over the last 12 months.
BWAY's Profit vs Risk Rating (35) in the Medical Specialties industry is somewhat better than the same rating for DXR (94). This means that BWAY’s stock grew somewhat faster than DXR’s over the last 12 months.
BWAY's SMR Rating (67) in the Medical Specialties industry is in the same range as DXR (84). This means that BWAY’s stock grew similarly to DXR’s over the last 12 months.
BWAY's Price Growth Rating (37) in the Medical Specialties industry is in the same range as DXR (55). This means that BWAY’s stock grew similarly to DXR’s over the last 12 months.
DXR's P/E Growth Rating (2) in the Medical Specialties industry is significantly better than the same rating for BWAY (91). This means that DXR’s stock grew significantly faster than BWAY’s over the last 12 months.
| BWAY | DXR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 81% | 2 days ago 77% |
| Stochastic ODDS (%) | 2 days ago 81% | 2 days ago 75% |
| Momentum ODDS (%) | 2 days ago 83% | 2 days ago 73% |
| MACD ODDS (%) | 2 days ago 79% | 2 days ago 83% |
| TrendWeek ODDS (%) | 2 days ago 80% | 2 days ago 70% |
| TrendMonth ODDS (%) | 2 days ago 87% | 2 days ago 73% |
| Advances ODDS (%) | 9 days ago 85% | 6 days ago 69% |
| Declines ODDS (%) | 2 days ago 77% | 10 days ago 74% |
| BollingerBands ODDS (%) | 2 days ago 77% | 2 days ago 74% |
| Aroon ODDS (%) | 2 days ago 87% | 2 days ago 85% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| VGIRX | 15.90 | 0.23 | +1.47% |
| Virtus Duff & Phelps Global Infras R6 | |||
| TCVYX | 25.34 | 0.16 | +0.64% |
| Touchstone Mid Cap Value Y | |||
| DCCCX | 25.50 | 0.01 | +0.04% |
| Nomura Small Cap Core C | |||
| FOPAX | 22.04 | N/A | N/A |
| Fidelity Advisor Intl Sm Cap Opps A | |||
| SROAX | 13.85 | -0.17 | -1.21% |
| Calamos Antetokounmpo Sustainable Eqs A | |||
BWAY and
Correlation & Price change
A.I.dvisor tells us that BWAY and STIM have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BWAY and STIM's prices will move in lockstep.
| Ticker / NAME | Correlation To BWAY | 1D Price Change % | ||
|---|---|---|---|---|
| BWAY | 100% | -1.38% | ||
| STIM - BWAY | 32% Poorly correlated | -8.54% | ||
| ISRG - BWAY | 31% Poorly correlated | -3.59% | ||
| DCTH - BWAY | 31% Poorly correlated | -0.10% | ||
| OM - BWAY | 30% Poorly correlated | +1.41% | ||
| QSI - BWAY | 28% Poorly correlated | -0.91% | ||
More | ||||
DXR and
Correlation & Price change
A.I.dvisor tells us that DXR and IART have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DXR and IART's prices will move in lockstep.
| Ticker / NAME | Correlation To DXR | 1D Price Change % | ||
|---|---|---|---|---|
| DXR | 100% | +2.66% | ||
| IART - DXR | 33% Poorly correlated | -3.41% | ||
| BWAY - DXR | 27% Poorly correlated | -1.38% | ||
| NOTV - DXR | 24% Poorly correlated | -5.56% | ||
| QIPT - DXR | 23% Poorly correlated | N/A | ||
| COO - DXR | 20% Poorly correlated | -1.64% | ||
More | ||||